Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review
By
- AMS
posted
Sep 25, 2020 07:23 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review
- AMS
Added May 25, 2020
Blog Entry
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
- AMS
Added Aug 13, 2021
Blog Entry
United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors
- AMS
Added Feb 20, 2020
Blog Entry
Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics
- AMS
Added Aug 05, 2020
Blog Entry
Temporal comparison of biologic medication prices between the United States and Australia
- AMS
Added Jun 01, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic